Profound Medical (TSE:PRN) Shares Up 0.3%

Profound Medical Corp. (TSE:PRN) shares traded up 0.3% during mid-day trading on Monday . The stock traded as high as C$10.92 and last traded at C$10.76. 5,830 shares were traded during mid-day trading, a decline of 18% from the average session volume of 7,076 shares. The stock had previously closed at C$10.73.

Profound Medical Price Performance

The stock has a market capitalization of C$263.40 million, a PE ratio of -6.48 and a beta of 0.83. The company has a debt-to-equity ratio of 16.95, a current ratio of 8.61 and a quick ratio of 14.98. The firm’s 50 day simple moving average is C$12.45 and its 200 day simple moving average is C$11.65.

Profound Medical (TSE:PRN) last posted its quarterly earnings results on Thursday, August 8th. The company reported C($0.38) earnings per share (EPS) for the quarter, meeting the consensus estimate of C($0.38). The business had revenue of C$3.06 million for the quarter, compared to analysts’ expectations of C$3.42 million. As a group, equities analysts forecast that Profound Medical Corp. will post -1.9000001 EPS for the current fiscal year.

Insider Buying and Selling at Profound Medical

In other Profound Medical news, Senior Officer Rashed Osman Dewan purchased 9,765 shares of Profound Medical stock in a transaction that occurred on Thursday, August 15th. The shares were bought at an average price of C$12.85 per share, for a total transaction of C$125,480.25. Corporate insiders own 8.66% of the company’s stock.

Profound Medical Company Profile

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum.